top of page
Trial title:
A Phase 1-2 master protocol to study intravenous ATTR-01 in adult participants with select epithelial solid tumours under multiple sub-protocols (ATTEST) 
Trocept-One_logo_white.png

ATTEST clinical trial testing TROCEPT-01 (ATTR-01),
a novel ‘tumour-activated’ Immunotherapy for
solid cancers

AT_Trocept-cancer-drug_v3_1920px.png
The aim of this trial
ATTEST is a Phase 1 trial which is testing a new drug TROCEPT-01 (called ATTR-01 in the clinic) to find out if it may work to treat different types of solid cancers.  ATTR-01 is the first drug using the TROCEPT platform.
How does
Trocept_logo-design_4h.png
work?
TROCEPT-01 (ATTR-01)
is injected into a vein and finds the cancer.
1
TROCEPT-01 (ATTR-01) only enters cancer cells.
2
TROCEPT-01 (ATTR-01)
delivers the gene for a checkpoint inhibitor into tumor, causing it to make and secrete the active checkpoint inhibitor inside the tumour.

Checkpoint inhibitor released from cancer cell

3
TROCEPT-01 (ATTR-01)
only replicates in, and kills, cancer cells, turning cold tumors hot. This can boost the anti-tumour effect of the checkpoint inhibitor.

Dying cancer cell

Trocept kills cancer cells

4
TROCEPT-01 (ATTR-01)
enables a checkpoint inhibitor to be made only inside of the cancer. 
5

Checkpoint inhibitor and TROCEPT only build up in the cancer

Single_Cell_Gradient_8f_1920x1080.jpg
Cancer types included in the ATTEST clinical trial:
1
2
3
4
5
6
Head and neck cancer
Non-Small cell Lung cancer
Pancreatic cancer
Cholangiocarcinoma
Bladder cancer
Endometrial cancer
AT_male-female-bodies_4e_cutout.png
1
2
3
4
5
6
AT_Trocept-trial-patient_v2f.png
ATTEST - UK registered clinical study
What is the status of the ATTEST trial?
The trial opened to recruitment in March 2025.

Who is the ATTEST trial sponsor?
Accession Therapeutics Limited (UK)

Where is the ATTEST trial registered?
​You'll find us on ISRCTN 
bottom of page